Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
fludarabine + darbepoetin alfa
- Development stage
- Phase 3
- Lead developer
- Amgen
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Administration
- Intravenous, Subcutaneous
01
Overview
This is a combination therapy consisting of fludarabine, a purine analog antimetabolite chemotherapeutic agent, and darbepoetin alfa, an erythropoiesis-stimulating agent. Fludarabine inhibits DNA synthesis by interfering with DNA polymerase alpha, ribonucleotide reductase, and DNA primase after intracellular conversion to its active triphosphate form. It is primarily used in the treatment of B-cell chronic lymphocytic leukemia (CLL) and other hematologic malignancies[6][8]. Darbepoetin alfa is a recombinant erythropoietin analog that stimulates red blood cell production by binding to the erythropoietin receptor on erythroid progenitor cells in the bone marrow; it is used to treat anemia associated with chemotherapy or chronic kidney disease[9][5]. The combination has been studied in older patients with CLL and comorbidities to address both cancer control (via fludarabine) and chemotherapy-induced anemia (via darbepoetin)[1][4].
- Other names
- fludarabine + darbepoetinfludarabine + darbepoetin alfa
02
Targets
POLA1 (DNA polymerase alpha)DNA-directed primase/polymerase protein (PrimPol)Erythropoietin ReceptorRRM1
Beyond the preview
Go deeper on fludarabine + darbepoetin alfa.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on fludarabine + darbepoetin alfa.